The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 16, 2021

Filed:

Jul. 14, 2015
Applicants:

Daiichi Sankyo Company, Limited, Tokyo, JP;

Heartseed Inc., Tokyo, JP;

Inventors:

Fumiyuki Hattori, Osaka, JP;

Keiichi Fukuda, Tokyo, JP;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/00 (2006.01); A61K 35/34 (2015.01); A61L 27/38 (2006.01); C12N 5/077 (2010.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
A61K 35/34 (2013.01); A61L 27/3826 (2013.01); A61L 27/3895 (2013.01); C12N 5/0657 (2013.01); A61K 35/12 (2013.01); A61L 2430/20 (2013.01); C12N 2500/25 (2013.01); C12N 2500/90 (2013.01); C12N 2500/99 (2013.01); C12N 2501/105 (2013.01); C12N 2501/11 (2013.01); C12N 2501/115 (2013.01); C12N 2501/117 (2013.01); C12N 2501/12 (2013.01); C12N 2501/125 (2013.01); C12N 2501/13 (2013.01); C12N 2501/135 (2013.01); C12N 2501/235 (2013.01); C12N 2501/33 (2013.01); C12N 2501/998 (2013.01); C12N 2506/00 (2013.01); C12N 2506/02 (2013.01); C12N 2506/03 (2013.01); C12N 2506/04 (2013.01); C12N 2506/45 (2013.01);
Abstract

The object of the present invention is to improve the post-transplantation engraftment rate of cardiomyocytes that have been purified to such an extent that they are free from non-cardiomyocytes and any components derived from other species. To solve this problem, the present inventors studied the possibility of constructing cell masses from the purified cardiomyocytes. As a result, they revealed that the stated problem could be solved by providing a method of preparing cell masses of cardiomyocytes derived from pluripotent stem cells, characterized in that cell masses of aggregated cells containing cardiomyocytes that had been differentiated and induced from pluripotent stem cells were dispersed to single cells to thereby obtain purified cardiomyocytes, which were then cultured in a culture medium under serum-free conditions so that they were reaggregated.


Find Patent Forward Citations

Loading…